Biopharma deal-making returned to the fore during the first half of 2013, with 368 licenses and joint ventures (JV) compared to 265 during the first six months of 2012 – a 39 percent surge, according to Thomson Reuters Recap. All told, Recap captured 1,234 life science deals during the first half of the year, with licenses and JVs representing 30 percent of the total.